ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC
Final OS analysis from ARCHESПодробнее
ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamideПодробнее
ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spreadПодробнее
ENZAMET trialПодробнее
ARCHES trial: enzalutamide plus ADT for mHSPCПодробнее
ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPCПодробнее
ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPCПодробнее
Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES TrialПодробнее
Genomic characterization of patients with de-novo high-volume mCSPC compared to those withoutПодробнее
Prevalence of DDR alterations in patients with mHSPC enrolled in ARCHESПодробнее
mHSPC: Chemo-hormonal Therapy and Treatment IntensificationПодробнее
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Подробнее
Update on overall survival in ARCHES trialПодробнее
ARCHES trialПодробнее
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPCПодробнее
Is There Still a Role for Docetaxel in mHSPC?Подробнее
Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPCПодробнее
Is there still a role for docetaxel in mHSPC?Подробнее
Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPCПодробнее